Innogen的重量损失药物显示了希望,其目的是与Novo Nordisk的后专利后微硫化物进行竞争。 Innogen's weight-loss drug shows promise, aiming to compete with Novo Nordisk's semaglutide post-patent.

中国制药商Innogen预计到2023年完成对其重量损失药物efsubaglutide alfa的后期试验。 Chinese drugmaker Innogen expects to finish a late-stage trial of its weight-loss drug, efsubaglutide alfa, by 2023. 该药物显示了早期的希望,用户在4周内体重损失了7%左右。 The drug showed early promise with users losing about 7% of their body weight in four weeks. 在中国获准用于糖尿病,efsubaglutide alfa与Novo Nordisk的semaglutide竞争,该公司的专利将于2026年到期. Approved in China for diabetes, efsubaglutide alfa competes with Novo Nordisk's semaglutide, whose patent expires in 2026. 随着重量损失药物的增加,价格竞争可能成为一个重要因素。 As more weight-loss drugs emerge, price competition may become a significant factor.